Dr. Camidge on a Phase I Study With AZD9291 in NSCLC

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.

AZD9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations and seemed to be well tolerated in the trial. Camidge says he found it interesting that some patients did have a little bit of rash, possibly indicating that researchers are already approaching the ideal dose. AZD9291 demonstrated about a 46% response rate overall and about a 56% response rate in T790M+ patients.

Right now, Camidge says, AZD9291 could be a "game-changer," and anticipates a fast-track approval.

<<<

View more from the 2013 European Cancer Congress